Please login to the form below
BACE inhibitor
This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck acquires pre-clinical biotech Calporta for up to $576m
Merck, among many big pharma players, has had its fair share of failure in the neurodegenerative research area – its lead BACE inhibitor verubecestat failed to show a clinical effect in
Latest news
-
Biogen and Eisai drop Alzheimer’s drug elenbecestat
The sadly predictable pattern of the BACE inhibitor category is taking a familiar shape, with candidates being routinely abandoned in the late research stages. ... BACE inhibitor drugs target the beta amyloid cleaving enzyme (BACE), which plays a key
-
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
Novartis and Amgen researchers were well aware of these problems seen in earlier BACE inhibitor trials, but had not detected them in their own early trials. ... The loss of CNP520 leaves just one major BACE inhibitor standing – Eisai and Biogen’s
-
Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022
The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... BACE inhibitors are designed to an enzyme involved in the
-
Eisai to tackle dementia in new US research facility
Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and
-
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom
Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Deal Watch table for September 2014
Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
-
Pharma deals during September 2014
The product, an oral PK13 delta inhibitor appears to have completed phase 2 the stage when most options would expire. ... AstraZeneca and Lilly have announced a joint development and commercialisation deal for AstraZeneca's BACE inhibitor in phase I for
-
Eisai: Bucking the trend with R&D growth
BACE inhibitor E2609.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- COVID-19 could be key in identifying viruses with pandemic potential
- Novo Nordisk Foundation commits €127m for new cell therapy facility
- Alzheimer’s Research UK launches ‘Change The Ending’ campaign
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
